logo
Share SHARE
FONT-SIZE Plus   Neg

Actavis Reveals Court Injunction On Generic Pulmicort RESPULES Distribution

Actavis Inc. (ACT) Friday confirmed that the United States Court of Appeals for the Federal Circuit has granted a motion by AstraZeneca (AZN,AZN.L) to enjoin Actavis from further distribution of its generic version of AstraZeneca's Pulmicort RESPULES (budesonide inhalation suspension) 0.25, 0.5 mg products, pending resolution of AstraZeneca's appeal before the Court.

As a condition of the injunction, the Court has also ordered that AstraZeneca post a bond of $72 million.

Actavis launched its generic product on April 1, 2013, following a ruling from the U.S. District Court for the District of New Jersey that Actavis' 0.25, 0.5 and 1 mg generic version of Pulmicort RESPULES did not infringe United States Patent No. 7,524,834 and that United States Patent No. 6,598,603 was invalid.

On April 2, 2013, the District Court issued a temporary restraining order prohibiting sales of Actavis' generic product to permit AstraZeneca an opportunity to seek injunctive relief with the Federal Circuit.

Pulmicort RESPULES is a maintenance medicine used to control and prevent asthma symptoms in children ages 12 months to 8 years. For the 12 months ended January 31, 2013, total U.S. brand and generic sales of Pulmicort RESPULES were approximately $1.2 billion.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Verizon Communications Inc. (VZ) reported Thursday flat profit in the third-quarter 2017, but quarterly total consolidated operating revenues increased 2.5 percent from the prior year. The adjusted earnings per share met analysts' expectations. The company reaffirmed outlook for its fiscal year 2017. But it now expects capital spending for 2017 to be at the lower end of the prior range. Swiss nutrition, health and wellness giant Nestle SA reported a slight decline in reported sales for the nine-month period, reflecting divestments and negative currency impact. Organic sales growth was 2.6 percent, supported by improved real internal growth or RIG of 1.8 percent and pricing of 0.8 percent. The company now projects trading operating profit margin to decrease by 40-60 basis points.. While Democrats have largely been critical of the Republican tax reform plan, President Donald Trump has claimed the proposal has some bipartisan support. Trump suggested to reporters ahead of a meeting with members of the Senate Finance Committee on Wednesday that "people on both sides" support the tax reform plan.
comments powered by Disqus
Follow RTT